---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-000100"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-01-03T23:59:59+00:00"
generated_at: "2026-06-27T21:28:14.412007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anebulo doses first patient in Phase 2 study of ANEB-001 for acute cannabinoid intoxication; expects topline in 1H 2022

## Summary
- First patient dosed in Phase 2 proof-of-concept study evaluating ANEB-001 for acute cannabinoid intoxication.
- Part A will enroll 60 patients randomized 1:1:1 to 50mg, 100mg ANEB-001 or placebo, all receiving 10.5mg THC challenge.
- Initial topline results from Part A expected in first half of 2022.
- FDA pre-IND meeting provided guidance; Anebulo expects to submit IND in Q1 2022.
- FDA accepted a THC challenge model for efficacy; company plans MIDD paired-meeting request.

## SEC filing metadata
- accession: 0001493152-22-000100
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000100/0001493152-22-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000100/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-000100
- JSON: https://secwatch.observer/filing/0001493152-22-000100.json
- Plain text: https://secwatch.observer/filing/0001493152-22-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.